The FDA has granted fast track designation to BMS-986446, an anti–microtubule binding region tau antibody in phase 2 trials for early Alzheimer disease.
The European Commission granted marketing authorization for the Lilly mAb based on data from the phase 3 TRAILBLAZER-ALZ 2 and 6 clinical trials.
A study of more than 559 000 adults and 2.4 million genetic samples found that alcohol consumption of any amount increases dementia risk, challenging prior evidence of protective effects from light drinking.
FDA grants Fast Track designation to etalanetug, a promising tau-targeting antibody for Alzheimer disease that could expand treatment options for the neurodegenerative disease.
Among 180+ active AD trials, 15 biological targets span traditional Aβ and tau proteins as well as new pathways in brain metabolism, neuroinflammation, and synaptic health.
Your daily dose of the clinical news you may have missed.
Once-daily blarcamesine was associated with minimal cognitive decline at 48 weeks, with changes comparable to those observed in prodromal aging.
The FDA has cleared Eisai and Biogen’s Leqembi Iqlik, the first at-home subcutaneous autoinjector for maintenance therapy in patients with early Alzheimer disease.
Your daily dose of the clinical news you may have missed.
The protective effect of the diet was strongest in the highest-risk group, those homozygous for the APOE4 gene variant, suggesting that diet may help offset genetic risk.